| Patents for A61P 19 - Drugs for skeletal disorders (81,981) |
|---|
| 03/07/2002 | CA2420832A1 Methods and reagents for protease inhibition |
| 03/07/2002 | CA2420823A1 Use of a composition comprising an extract of pollen for the treatment of irritability |
| 03/07/2002 | CA2420667A1 Quinoline-(c=o)-(di-,tri- and tetrapeptide) derivatives as caspase inhibitors |
| 03/07/2002 | CA2420659A1 Genes expressed in the cell cycle |
| 03/07/2002 | CA2420591A1 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |
| 03/07/2002 | CA2420286A1 7-oxo pyridopyrimidines as inhibitors of a cellular proliferation |
| 03/07/2002 | CA2420122A1 7-oxo pyridopyrimidines |
| 03/07/2002 | CA2419935A1 Collagen/polysaccharide bilayer matrix |
| 03/07/2002 | CA2419841A1 Novel cd40:cd154 binding interruptor compounds and use thereof to treat immunological complications |
| 03/07/2002 | CA2419699A1 Gem-substituted .alpha. v .beta. 3 integrin antagonists |
| 03/07/2002 | CA2419606A1 Lung surfactant compositions with dynamic swelling behaviour |
| 03/07/2002 | CA2419483A1 Methods and devices for quantitative analysis of x-ray images |
| 03/07/2002 | CA2419255A1 Compounds containing a bicyclic ring system useful as alpha v beta 3 antagonists |
| 03/07/2002 | CA2419249A1 Water-dispersible encapsulated sterols |
| 03/07/2002 | CA2419152A1 Methods of using agents that modulate bone formation and inhibit adipogenesis |
| 03/07/2002 | CA2382687A1 A therapeutic agent of osteoporosis comprising an active ingredient of quercetin derivatives |
| 03/06/2002 | EP1184036A2 Heterocyclic compounds, their production and use as tachykinin receptor antagonists |
| 03/06/2002 | EP1183353A1 Modified chimeric polypeptides with improved pharmacokinetic properties |
| 03/06/2002 | EP1183351A1 Phospholipid transfer protein |
| 03/06/2002 | EP1183333A1 Methods of using rnase p reaction mechanisms of action |
| 03/06/2002 | EP1183259A2 Azepinoindole derivatives, the production and use thereof |
| 03/06/2002 | EP1183258A1 Imidazo-containing heterocyclic compounds, their compositions and uses |
| 03/06/2002 | EP1183252A1 New pharmaceutically active compounds |
| 03/06/2002 | EP1183241A1 Spiroimidazolidine derivatives, their preparation, their use and pharmaceutical preparations comprising them |
| 03/06/2002 | EP1183239A1 Aromatic sulfone hydroxamic acid metalloprotease inhibitor |
| 03/06/2002 | EP1183233A2 Bradykinin receptor antagonists |
| 03/06/2002 | EP1183074A1 Substituted biaryl ether compounds |
| 03/06/2002 | EP1183040A1 Therapeutic use of an inhibitor of a hedgehog or a hedgehog-related signalling pathway |
| 03/06/2002 | EP1183039A1 Pharmaceutical preparations of bioactive substances extracted from natural sources |
| 03/06/2002 | EP1183037A2 Methods and compositions for modulating immune response and for the treatment of inflammatory disease |
| 03/06/2002 | EP1183028A2 New use of macrolide compounds for inducing chondrogenic differentiation |
| 03/06/2002 | EP1183020A2 Use of(-)(3-trihalomethylphenoxy) (4-halophenyl)acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidaemia and hyperuricaemia |
| 03/06/2002 | EP1183019A2 Ace-2 inhibiting compounds and methods of use thereof |
| 03/06/2002 | EP1182929A1 Osteonectin based toxic gene therapy for the treatment of calcified tumors and tissues |
| 03/06/2002 | CN1339032A Reverse hydroxamate inhibitors of matrix metalloproteinases |
| 03/06/2002 | CN1339028A Pyrimidine-2,4,6-triones as inhibitors of matrix metalloproteinases |
| 03/06/2002 | CN1338940A Bidifobacterium in the treatment of inflammatory disease |
| 03/06/2002 | CN1338923A Method for controlling liposome size |
| 03/06/2002 | CN1338301A Medicinal pill for preventing and treating hyperosteogeny |
| 03/06/2002 | CN1338299A Chinese medicine for treating bone fracture |
| 03/06/2002 | CN1338297A Orally applied medicine 'Gukangwang' for treating arthropathy and its preparing process |
| 03/06/2002 | CN1338282A Bone-setting medicine and its preparing process |
| 03/06/2002 | CN1338264A Bafengjietong plaster |
| 03/06/2002 | CN1338262A Compound monkshood rhizome cream and its preparing process |
| 03/06/2002 | CN1080260C Substituted indazole derivatives and their use as phosphodiesterase (PDE) type IV and tumor necrosis factor (TNF) inhibitors |
| 03/05/2002 | US6353018 Compounds, their preparation and use |
| 03/05/2002 | US6353010 Enzyme inhibitors tumor necrosis factor and phosphodiesterase for antiinflammatory agents |
| 03/05/2002 | US6353009 Method for the treatment and prevention of hyperuricemia |
| 03/05/2002 | US6352974 Oral calcitonin pharmaceutical compositions and methods of making the same |
| 03/05/2002 | US6352971 Polypeptides with amino acid sequences |
| 03/05/2002 | US6352970 Treatment of skeletal disorders |
| 03/05/2002 | CA2098735C Novel methylenebisphosphonic acid derivatives |
| 03/05/2002 | CA2098732C Novel methylenebisphosphonic acid derivatives |
| 02/28/2002 | WO2002016615A2 Crystal structure of dimethylarginine dimethylaminohydrolase and arginine deiminase |
| 02/28/2002 | WO2002016557A2 Tissue engineering scaffolds promoting matrix protein production |
| 02/28/2002 | WO2002016553A2 Regulator gene and system useful for the diagnosis and therapy of osteoporosis |
| 02/28/2002 | WO2002016436A2 ANTIBODIES TO HUMAN IL-1$g(b) |
| 02/28/2002 | WO2002016434A1 T CELL RECEPTOR Vβ-Dβ-Jβ SEQUENCE AND METHODS FOR ITS DETECTION |
| 02/28/2002 | WO2002016394A1 Thioether-sulphamate steroids as steroid sulphatase inhibitors and anti-cancer compounds |
| 02/28/2002 | WO2002016393A1 17-aryl-linker derivatised estrogen 3-sulphamates as inhibitors of steroid sulphatase |
| 02/28/2002 | WO2002016392A1 Oestrogen-17-sulphamates as inhibitors of steroid sulphatase |
| 02/28/2002 | WO2002016381A2 Composition and method for inhibiting platelet aggregation |
| 02/28/2002 | WO2002016370A1 1h-imidazopyridine derivatives |
| 02/28/2002 | WO2002016359A1 Fused pyrazole derivatives being protein kinase inhibitors |
| 02/28/2002 | WO2002016352A1 Quinazoline derivatives |
| 02/28/2002 | WO2002016326A1 Heterocyclic-hydroxyimino-fluorenes and their use for inhibiting protein kinases |
| 02/28/2002 | WO2002016318A1 Novel thiourea derivatives and the pharmaceutical compositions containing the same |
| 02/28/2002 | WO2002016316A1 10-ARYL-11-HBENZO [b]FLUORENE DERIVATIVES AND ANALOGS FOR MEDICINAL USE |
| 02/28/2002 | WO2002016313A2 Integrin receptor inhibitors |
| 02/28/2002 | WO2002016311A1 Carboxylic acid derivatives, process for producing the same and drugs containing the same as the active ingredient |
| 02/28/2002 | WO2002016310A1 Selective androgen receptor modulators and methods of use thereof |
| 02/28/2002 | WO2002015923A1 Orally administered peptides to ameliorate atherosclerosis |
| 02/28/2002 | WO2002015920A2 Treatment of hyperproliferative diseases |
| 02/28/2002 | WO2002015918A2 Method and compositions for promoting osteogenesis |
| 02/28/2002 | WO2002015916A1 Use of dihydroboswellic acids or hydrogenated extracts of boswellia for prophylactic and/or therapeutic treatment |
| 02/28/2002 | WO2002015894A2 Use of vitamin d derivatives as bone resorption inhibitors |
| 02/28/2002 | WO2002015886A2 Oral fast-melt dosage form of a cyclooxygenase-2 inhibitor |
| 02/28/2002 | WO2002015885A2 Oral fast-melt formulation of a cyclooxygenase-2 inhibitor |
| 02/28/2002 | WO2002015884A2 Rapidly disintegrating oral formulation of a cyclooxygenase-2 inhibitor |
| 02/28/2002 | WO2002015881A2 Use of a porous carrier |
| 02/28/2002 | WO2002015846A2 Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders |
| 02/28/2002 | WO2001087234A3 Treatment of autoimmune, proliferative and inflammatory diseases with compositions of non-ionic copolymers |
| 02/28/2002 | WO2001079271A9 Albumin fusion proteins |
| 02/28/2002 | WO2001079258A9 Albumin fusion proteins |
| 02/28/2002 | WO2001076530A3 Il-8 receptor antagonists |
| 02/28/2002 | WO2001072281A3 Microspheres for active embolization |
| 02/28/2002 | WO2001070720A3 Carbocyclic side chain containing, n-substituted metalloprotease inhibitors |
| 02/28/2002 | WO2001068845A3 Inflammation-inducible hybrid promoters, vectors containing same and uses thereof |
| 02/28/2002 | WO2001068654A3 Tubulin binding ligands and corresponding prodrug constructs |
| 02/28/2002 | WO2001064639A3 Pde iv inhibiting amides, compositions and pharmaceutical use |
| 02/28/2002 | WO2001049309A3 Combinations of growth factors and i: upa or i: mmp for the treatment of damaged tissue |
| 02/28/2002 | WO2001046200A8 Novel piperidine and piperazine derivatives |
| 02/28/2002 | WO2001045714A3 Formulations of adenosine a1 agonists |
| 02/28/2002 | WO2001043755A3 Regenerative adjuvant (3-way tap) |
| 02/28/2002 | WO2001042216A3 Caspase inhibitors and uses thereof |
| 02/28/2002 | WO2001031029A3 Human sphingosine kinase gene |
| 02/28/2002 | WO2001027254A3 Gene transfer vectors for treating autoimmune diseases and diseases with immunopathogenesis by therapy |
| 02/28/2002 | WO2001005422A3 Use of a polypeptide for detecting, preventing or treating a pathological condition associated with a degenerative, neurological or autoimmune disease |
| 02/28/2002 | WO2001001970A3 New uses potassium channel openers, such as the treatment of epilepsy |
| 02/28/2002 | WO2000067746A8 Carboxylic acid derivatives that inhibit the binding of integrins to their receptors |